vitro against several pathogenic representative gram Search Results


99
ATCC foodborne pathogenic bacteria reference strains
Foodborne Pathogenic Bacteria Reference Strains, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/foodborne pathogenic bacteria reference strains/product/ATCC
Average 99 stars, based on 1 article reviews
foodborne pathogenic bacteria reference strains - by Bioz Stars, 2026-05
99/100 stars
  Buy from Supplier

94
ATCC human pathogenic microorganism bacillus subtilis
Human Pathogenic Microorganism Bacillus Subtilis, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human pathogenic microorganism bacillus subtilis/product/ATCC
Average 94 stars, based on 1 article reviews
human pathogenic microorganism bacillus subtilis - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier

99
ATCC pathogens yeast candida albicans
Pathogens Yeast Candida Albicans, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pathogens yeast candida albicans/product/ATCC
Average 99 stars, based on 1 article reviews
pathogens yeast candida albicans - by Bioz Stars, 2026-05
99/100 stars
  Buy from Supplier

94
ATCC mouse isolate e coli a3
Treatment with GAS914 impacts GalT-KO mice survival after CLP. (A) DNA stratification by pulsed-field gel electrophoresis (PFGE) of <t>E</t> <t>coli</t> isolated from mouse blood after 12 h – 24 h of CLP in GalT-KO mice treated with GAS914 (n = 8) or PBS (n = 8). (B) Influence of GAS914 or PBS treatment on GalT-KO mouse survival after CLP in animals treated before and after the procedure (left, n = 17) or beginning the treatment 12 h after CLP (right, n = 14). Data are represented in Kaplan-Maier curves and were compared using the long-rank (Mantel-Cox) test, **P < 0.01.
Mouse Isolate E Coli A3, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse isolate e coli a3/product/ATCC
Average 94 stars, based on 1 article reviews
mouse isolate e coli a3 - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier

99
ATCC human fungal pathogen
Treatment with GAS914 impacts GalT-KO mice survival after CLP. (A) DNA stratification by pulsed-field gel electrophoresis (PFGE) of <t>E</t> <t>coli</t> isolated from mouse blood after 12 h – 24 h of CLP in GalT-KO mice treated with GAS914 (n = 8) or PBS (n = 8). (B) Influence of GAS914 or PBS treatment on GalT-KO mouse survival after CLP in animals treated before and after the procedure (left, n = 17) or beginning the treatment 12 h after CLP (right, n = 14). Data are represented in Kaplan-Maier curves and were compared using the long-rank (Mantel-Cox) test, **P < 0.01.
Human Fungal Pathogen, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human fungal pathogen/product/ATCC
Average 99 stars, based on 1 article reviews
human fungal pathogen - by Bioz Stars, 2026-05
99/100 stars
  Buy from Supplier

99
ATCC agar disk diffusion method against reference pathogenic strains
Treatment with GAS914 impacts GalT-KO mice survival after CLP. (A) DNA stratification by pulsed-field gel electrophoresis (PFGE) of <t>E</t> <t>coli</t> isolated from mouse blood after 12 h – 24 h of CLP in GalT-KO mice treated with GAS914 (n = 8) or PBS (n = 8). (B) Influence of GAS914 or PBS treatment on GalT-KO mouse survival after CLP in animals treated before and after the procedure (left, n = 17) or beginning the treatment 12 h after CLP (right, n = 14). Data are represented in Kaplan-Maier curves and were compared using the long-rank (Mantel-Cox) test, **P < 0.01.
Agar Disk Diffusion Method Against Reference Pathogenic Strains, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/agar disk diffusion method against reference pathogenic strains/product/ATCC
Average 99 stars, based on 1 article reviews
agar disk diffusion method against reference pathogenic strains - by Bioz Stars, 2026-05
99/100 stars
  Buy from Supplier

99
ATCC formulations against e coli atcc 25922
Treatment with GAS914 impacts GalT-KO mice survival after CLP. (A) DNA stratification by pulsed-field gel electrophoresis (PFGE) of <t>E</t> <t>coli</t> isolated from mouse blood after 12 h – 24 h of CLP in GalT-KO mice treated with GAS914 (n = 8) or PBS (n = 8). (B) Influence of GAS914 or PBS treatment on GalT-KO mouse survival after CLP in animals treated before and after the procedure (left, n = 17) or beginning the treatment 12 h after CLP (right, n = 14). Data are represented in Kaplan-Maier curves and were compared using the long-rank (Mantel-Cox) test, **P < 0.01.
Formulations Against E Coli Atcc 25922, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/formulations against e coli atcc 25922/product/ATCC
Average 99 stars, based on 1 article reviews
formulations against e coli atcc 25922 - by Bioz Stars, 2026-05
99/100 stars
  Buy from Supplier

99
ATCC vitro antimycobacterial property against pathogenic m tuberculosis h37rv strain
Recently published patents of benzimidazole derivatives.
Vitro Antimycobacterial Property Against Pathogenic M Tuberculosis H37rv Strain, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/vitro antimycobacterial property against pathogenic m tuberculosis h37rv strain/product/ATCC
Average 99 stars, based on 1 article reviews
vitro antimycobacterial property against pathogenic m tuberculosis h37rv strain - by Bioz Stars, 2026-05
99/100 stars
  Buy from Supplier

99
ATCC livestock pathogens
Recently published patents of benzimidazole derivatives.
Livestock Pathogens, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/livestock pathogens/product/ATCC
Average 99 stars, based on 1 article reviews
livestock pathogens - by Bioz Stars, 2026-05
99/100 stars
  Buy from Supplier

99
ATCC pathogens in vitro
Recently published patents of benzimidazole derivatives.
Pathogens In Vitro, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pathogens in vitro/product/ATCC
Average 99 stars, based on 1 article reviews
pathogens in vitro - by Bioz Stars, 2026-05
99/100 stars
  Buy from Supplier

95
ATCC gut pathogen shigella flexneri
a Schematic of oral delivery of REcN encapsulated in silk plastics for enhanced probiotic viability through the digestive system. b Photograph of WS/REcN and schematic illustrating REcN embedded within a protective, high-crystallinity silk shell (Scale bar: 5 mm). c SEM images of silk/REcN powders (Scale bar: 500 nm). d SEM images of WS/REcN (left) and individual REcN embedded in silk (right) (Scale bars: 5 μm left, 500 nm right). e Remaining viability of REcN from silk/REcN, TS/REcN, and WS/REcN ( n = 3 independent replicates, P = 0.3421 (silk/REcN vs. TS/REcN), P = 0.3261 (silk/REcN vs. WS/REcN), P = 0.9991 (TS/REcN vs. WS/REcN)). f Remaining viability of S-REcN (SGF <t>+</t> <t>SIF-treated</t> REcN), ST-REcN (REcN released from SGF + SIF-treated TS/REcN), and SW-REcN (REcN released from SGF + SIF-treated WS/REcN) ( n = 5 independent replicates, P ≤ 0.0001 (SW-REcN vs. ST-REcN), P ≤ 0.0001 (SW-REcN vs. S-REcN), P = 0.6245 (S-REcN vs. ST-REcN)). g Growth curves of fresh REcN, S-REcN, SW-REcN, and W-REcN (REcN released from untreated WS/REcN), measured by OD600 over 12 h ( n = 3 independent replicates, P ≤ 0.0001 (S-REcN vs. REcN or SW-REcN or W-REcN)). h Fluorescence microscopy images of SW-REcN and S-REcN (Green: SYTO-9, Red: RFP, Scale bar: 100 μm). i Schematic of in vitro antimicrobial activity of REcN and SW-REcN against Shigella <t>flexneri</t> ( S. flexneri ), with pathogen reduction quantified by plating on MacConkey agar ( n = 5 independent replicates, P = 0.364 (SW-REcN vs. REcN)). j In vivo probiotic resistance studies: orally administered REcN or WS/REcN with equivalent bacterial loads, with gastrointestinal tract imaging at 4 and 24 h post-administration ( n = 5 biological independent replicates). All data are mean values ± standard deviations. Statistical analysis: One-way ANOVA with Tukey’s multiple comparisons in ( e – g ) and Two-tailed unpaired t -test in ( i ) (**** P ≤ 0.0001, NS: not significant). i , j Created with BioRender.com released under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International license.
Gut Pathogen Shigella Flexneri, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gut pathogen shigella flexneri/product/ATCC
Average 95 stars, based on 1 article reviews
gut pathogen shigella flexneri - by Bioz Stars, 2026-05
95/100 stars
  Buy from Supplier

99
ATCC human pathogenic bacterial species
a Schematic of oral delivery of REcN encapsulated in silk plastics for enhanced probiotic viability through the digestive system. b Photograph of WS/REcN and schematic illustrating REcN embedded within a protective, high-crystallinity silk shell (Scale bar: 5 mm). c SEM images of silk/REcN powders (Scale bar: 500 nm). d SEM images of WS/REcN (left) and individual REcN embedded in silk (right) (Scale bars: 5 μm left, 500 nm right). e Remaining viability of REcN from silk/REcN, TS/REcN, and WS/REcN ( n = 3 independent replicates, P = 0.3421 (silk/REcN vs. TS/REcN), P = 0.3261 (silk/REcN vs. WS/REcN), P = 0.9991 (TS/REcN vs. WS/REcN)). f Remaining viability of S-REcN (SGF <t>+</t> <t>SIF-treated</t> REcN), ST-REcN (REcN released from SGF + SIF-treated TS/REcN), and SW-REcN (REcN released from SGF + SIF-treated WS/REcN) ( n = 5 independent replicates, P ≤ 0.0001 (SW-REcN vs. ST-REcN), P ≤ 0.0001 (SW-REcN vs. S-REcN), P = 0.6245 (S-REcN vs. ST-REcN)). g Growth curves of fresh REcN, S-REcN, SW-REcN, and W-REcN (REcN released from untreated WS/REcN), measured by OD600 over 12 h ( n = 3 independent replicates, P ≤ 0.0001 (S-REcN vs. REcN or SW-REcN or W-REcN)). h Fluorescence microscopy images of SW-REcN and S-REcN (Green: SYTO-9, Red: RFP, Scale bar: 100 μm). i Schematic of in vitro antimicrobial activity of REcN and SW-REcN against Shigella <t>flexneri</t> ( S. flexneri ), with pathogen reduction quantified by plating on MacConkey agar ( n = 5 independent replicates, P = 0.364 (SW-REcN vs. REcN)). j In vivo probiotic resistance studies: orally administered REcN or WS/REcN with equivalent bacterial loads, with gastrointestinal tract imaging at 4 and 24 h post-administration ( n = 5 biological independent replicates). All data are mean values ± standard deviations. Statistical analysis: One-way ANOVA with Tukey’s multiple comparisons in ( e – g ) and Two-tailed unpaired t -test in ( i ) (**** P ≤ 0.0001, NS: not significant). i , j Created with BioRender.com released under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International license.
Human Pathogenic Bacterial Species, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human pathogenic bacterial species/product/ATCC
Average 99 stars, based on 1 article reviews
human pathogenic bacterial species - by Bioz Stars, 2026-05
99/100 stars
  Buy from Supplier

Image Search Results


Treatment with GAS914 impacts GalT-KO mice survival after CLP. (A) DNA stratification by pulsed-field gel electrophoresis (PFGE) of E coli isolated from mouse blood after 12 h – 24 h of CLP in GalT-KO mice treated with GAS914 (n = 8) or PBS (n = 8). (B) Influence of GAS914 or PBS treatment on GalT-KO mouse survival after CLP in animals treated before and after the procedure (left, n = 17) or beginning the treatment 12 h after CLP (right, n = 14). Data are represented in Kaplan-Maier curves and were compared using the long-rank (Mantel-Cox) test, **P < 0.01.

Journal: Frontiers in Immunology

Article Title: Removal of natural anti-αGal antibodies elicits protective immunity against Gram-negative bacterial infections

doi: 10.3389/fimmu.2023.1232924

Figure Lengend Snippet: Treatment with GAS914 impacts GalT-KO mice survival after CLP. (A) DNA stratification by pulsed-field gel electrophoresis (PFGE) of E coli isolated from mouse blood after 12 h – 24 h of CLP in GalT-KO mice treated with GAS914 (n = 8) or PBS (n = 8). (B) Influence of GAS914 or PBS treatment on GalT-KO mouse survival after CLP in animals treated before and after the procedure (left, n = 17) or beginning the treatment 12 h after CLP (right, n = 14). Data are represented in Kaplan-Maier curves and were compared using the long-rank (Mantel-Cox) test, **P < 0.01.

Article Snippet: We also measured in vitro GalT-KO mice serum bactericidal activity, and the antibody and complement deposition against the pathogenic mouse isolate E. coli A3 and E. coli O86:B7 (ATCC ® 12701 TM ), a bacterium with high α-galactosyl content ( , ).

Techniques: Pulsed-Field Gel, Electrophoresis, Isolation

Treatment with GAS914 increases GalT-KO mice serum bactericidal capacity against E coli A3 isolated after CLP. (A) Effect of GAS914 and PBS in GalT-KO bactericidal activity against E coli A3. The bactericidal activity was calculated as the percentage of bacteria surviving in reaction mixtures containing the tested serum compared to the control (growth). Growth: control bacterial growth, ACP, alternative complement pathway; SMS, standard mouse serum. Individual data of PBS and GAS914 represent the mean of three experiments. (B) Median fluorescence intensity of IgG, IgM, C3, C4, and IgG subclasses on the surface of E coli A3 (n = 6). Individual data represents the mean of three experiments. Unpaired non-parametric Mann-Whitney test was used to compare PBS and GAS914 groups, ** P < 0.01.

Journal: Frontiers in Immunology

Article Title: Removal of natural anti-αGal antibodies elicits protective immunity against Gram-negative bacterial infections

doi: 10.3389/fimmu.2023.1232924

Figure Lengend Snippet: Treatment with GAS914 increases GalT-KO mice serum bactericidal capacity against E coli A3 isolated after CLP. (A) Effect of GAS914 and PBS in GalT-KO bactericidal activity against E coli A3. The bactericidal activity was calculated as the percentage of bacteria surviving in reaction mixtures containing the tested serum compared to the control (growth). Growth: control bacterial growth, ACP, alternative complement pathway; SMS, standard mouse serum. Individual data of PBS and GAS914 represent the mean of three experiments. (B) Median fluorescence intensity of IgG, IgM, C3, C4, and IgG subclasses on the surface of E coli A3 (n = 6). Individual data represents the mean of three experiments. Unpaired non-parametric Mann-Whitney test was used to compare PBS and GAS914 groups, ** P < 0.01.

Article Snippet: We also measured in vitro GalT-KO mice serum bactericidal activity, and the antibody and complement deposition against the pathogenic mouse isolate E. coli A3 and E. coli O86:B7 (ATCC ® 12701 TM ), a bacterium with high α-galactosyl content ( , ).

Techniques: Isolation, Activity Assay, Bacteria, Control, Fluorescence, MANN-WHITNEY

Neutralizing anti-αGal antibodies from human sera with GAS914 increases serum bactericidal killing and decreases IgG2 binding to Gram-negative bacteria. (A) Bactericidal killing after exposing the human sera to PBS or GAS914 against E coli O86:B7, P. aeruginosa 21565, and K pneumonia 35204 (n = 8). The bactericidal killing was calculated as the percentage of the number of bacteria surviving in reaction mixtures containing the tested serum compared to the control (growth). Growth: control bacterial growth, ACP, alternative complement pathway. Individual data of PBS and GAS914 represent the mean of three experiments. (B) Median fluorescence intensity of IgG, IgM, IgA, IgG subclasses, and complement C3 and C4 deposition on the surface of E coli O86:B7 (n = 8). Individual data represents the mean of three experiments. Comparisons were analyzed by paired t -tests, * P < 0.05, ** P < 0.01.

Journal: Frontiers in Immunology

Article Title: Removal of natural anti-αGal antibodies elicits protective immunity against Gram-negative bacterial infections

doi: 10.3389/fimmu.2023.1232924

Figure Lengend Snippet: Neutralizing anti-αGal antibodies from human sera with GAS914 increases serum bactericidal killing and decreases IgG2 binding to Gram-negative bacteria. (A) Bactericidal killing after exposing the human sera to PBS or GAS914 against E coli O86:B7, P. aeruginosa 21565, and K pneumonia 35204 (n = 8). The bactericidal killing was calculated as the percentage of the number of bacteria surviving in reaction mixtures containing the tested serum compared to the control (growth). Growth: control bacterial growth, ACP, alternative complement pathway. Individual data of PBS and GAS914 represent the mean of three experiments. (B) Median fluorescence intensity of IgG, IgM, IgA, IgG subclasses, and complement C3 and C4 deposition on the surface of E coli O86:B7 (n = 8). Individual data represents the mean of three experiments. Comparisons were analyzed by paired t -tests, * P < 0.05, ** P < 0.01.

Article Snippet: We also measured in vitro GalT-KO mice serum bactericidal activity, and the antibody and complement deposition against the pathogenic mouse isolate E. coli A3 and E. coli O86:B7 (ATCC ® 12701 TM ), a bacterium with high α-galactosyl content ( , ).

Techniques: Binding Assay, Bacteria, Control, Fluorescence

Length and expression level of lipopolysaccharide (LPS) O-antigen chains and αGal in Gram-negative bacteria. (A) Separation by SDS-PAGE (13%) of repeating oligosaccharide units of LPS extracted from Escherichia coli O86:B7 (lane 1), Pseudomonas aeruginosa 21565 (lane 2), Klebsiella pneumoniae 35204 (lane 3) and Escherichia coli A3 (lane 4). Standard LPS from E coli O111:B4 (lane 5, Sigma-Aldrich, St. Louis, MO, USA) was used as a reference. (B) Median fluorescence intensity of α-galactosyl expression with isolectin IB4 and αGal expression with anti-αGal IgM and IgG monoclonal antibodies in E coli A3, K pneumoniae 35204, P. aeruginosa 21565, and E coli O86:B7. Data are representative of three independent experiments.

Journal: Frontiers in Immunology

Article Title: Removal of natural anti-αGal antibodies elicits protective immunity against Gram-negative bacterial infections

doi: 10.3389/fimmu.2023.1232924

Figure Lengend Snippet: Length and expression level of lipopolysaccharide (LPS) O-antigen chains and αGal in Gram-negative bacteria. (A) Separation by SDS-PAGE (13%) of repeating oligosaccharide units of LPS extracted from Escherichia coli O86:B7 (lane 1), Pseudomonas aeruginosa 21565 (lane 2), Klebsiella pneumoniae 35204 (lane 3) and Escherichia coli A3 (lane 4). Standard LPS from E coli O111:B4 (lane 5, Sigma-Aldrich, St. Louis, MO, USA) was used as a reference. (B) Median fluorescence intensity of α-galactosyl expression with isolectin IB4 and αGal expression with anti-αGal IgM and IgG monoclonal antibodies in E coli A3, K pneumoniae 35204, P. aeruginosa 21565, and E coli O86:B7. Data are representative of three independent experiments.

Article Snippet: We also measured in vitro GalT-KO mice serum bactericidal activity, and the antibody and complement deposition against the pathogenic mouse isolate E. coli A3 and E. coli O86:B7 (ATCC ® 12701 TM ), a bacterium with high α-galactosyl content ( , ).

Techniques: Expressing, Bacteria, SDS Page, Fluorescence, Bioprocessing

Recently published patents of benzimidazole derivatives.

Journal: Frontiers in Pharmacology

Article Title: A Comprehensive Account on Recent Progress in Pharmacological Activities of Benzimidazole Derivatives

doi: 10.3389/fphar.2021.762807

Figure Lengend Snippet: Recently published patents of benzimidazole derivatives.

Article Snippet: A number of substituted fluorobenzimidazole derivatives ( 329–330 ) were synthesized and evaluated for in vitro antimycobacterial property against pathogenic M. tuberculosis H37Rv strain (ATCC 27294) using MABA method.

Techniques: Inhibition, Synthesized, Virus

a Schematic of oral delivery of REcN encapsulated in silk plastics for enhanced probiotic viability through the digestive system. b Photograph of WS/REcN and schematic illustrating REcN embedded within a protective, high-crystallinity silk shell (Scale bar: 5 mm). c SEM images of silk/REcN powders (Scale bar: 500 nm). d SEM images of WS/REcN (left) and individual REcN embedded in silk (right) (Scale bars: 5 μm left, 500 nm right). e Remaining viability of REcN from silk/REcN, TS/REcN, and WS/REcN ( n = 3 independent replicates, P = 0.3421 (silk/REcN vs. TS/REcN), P = 0.3261 (silk/REcN vs. WS/REcN), P = 0.9991 (TS/REcN vs. WS/REcN)). f Remaining viability of S-REcN (SGF + SIF-treated REcN), ST-REcN (REcN released from SGF + SIF-treated TS/REcN), and SW-REcN (REcN released from SGF + SIF-treated WS/REcN) ( n = 5 independent replicates, P ≤ 0.0001 (SW-REcN vs. ST-REcN), P ≤ 0.0001 (SW-REcN vs. S-REcN), P = 0.6245 (S-REcN vs. ST-REcN)). g Growth curves of fresh REcN, S-REcN, SW-REcN, and W-REcN (REcN released from untreated WS/REcN), measured by OD600 over 12 h ( n = 3 independent replicates, P ≤ 0.0001 (S-REcN vs. REcN or SW-REcN or W-REcN)). h Fluorescence microscopy images of SW-REcN and S-REcN (Green: SYTO-9, Red: RFP, Scale bar: 100 μm). i Schematic of in vitro antimicrobial activity of REcN and SW-REcN against Shigella flexneri ( S. flexneri ), with pathogen reduction quantified by plating on MacConkey agar ( n = 5 independent replicates, P = 0.364 (SW-REcN vs. REcN)). j In vivo probiotic resistance studies: orally administered REcN or WS/REcN with equivalent bacterial loads, with gastrointestinal tract imaging at 4 and 24 h post-administration ( n = 5 biological independent replicates). All data are mean values ± standard deviations. Statistical analysis: One-way ANOVA with Tukey’s multiple comparisons in ( e – g ) and Two-tailed unpaired t -test in ( i ) (**** P ≤ 0.0001, NS: not significant). i , j Created with BioRender.com released under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International license.

Journal: Nature Communications

Article Title: Living plastics from plasticizer-assisted thermal molding of silk protein

doi: 10.1038/s41467-024-55097-x

Figure Lengend Snippet: a Schematic of oral delivery of REcN encapsulated in silk plastics for enhanced probiotic viability through the digestive system. b Photograph of WS/REcN and schematic illustrating REcN embedded within a protective, high-crystallinity silk shell (Scale bar: 5 mm). c SEM images of silk/REcN powders (Scale bar: 500 nm). d SEM images of WS/REcN (left) and individual REcN embedded in silk (right) (Scale bars: 5 μm left, 500 nm right). e Remaining viability of REcN from silk/REcN, TS/REcN, and WS/REcN ( n = 3 independent replicates, P = 0.3421 (silk/REcN vs. TS/REcN), P = 0.3261 (silk/REcN vs. WS/REcN), P = 0.9991 (TS/REcN vs. WS/REcN)). f Remaining viability of S-REcN (SGF + SIF-treated REcN), ST-REcN (REcN released from SGF + SIF-treated TS/REcN), and SW-REcN (REcN released from SGF + SIF-treated WS/REcN) ( n = 5 independent replicates, P ≤ 0.0001 (SW-REcN vs. ST-REcN), P ≤ 0.0001 (SW-REcN vs. S-REcN), P = 0.6245 (S-REcN vs. ST-REcN)). g Growth curves of fresh REcN, S-REcN, SW-REcN, and W-REcN (REcN released from untreated WS/REcN), measured by OD600 over 12 h ( n = 3 independent replicates, P ≤ 0.0001 (S-REcN vs. REcN or SW-REcN or W-REcN)). h Fluorescence microscopy images of SW-REcN and S-REcN (Green: SYTO-9, Red: RFP, Scale bar: 100 μm). i Schematic of in vitro antimicrobial activity of REcN and SW-REcN against Shigella flexneri ( S. flexneri ), with pathogen reduction quantified by plating on MacConkey agar ( n = 5 independent replicates, P = 0.364 (SW-REcN vs. REcN)). j In vivo probiotic resistance studies: orally administered REcN or WS/REcN with equivalent bacterial loads, with gastrointestinal tract imaging at 4 and 24 h post-administration ( n = 5 biological independent replicates). All data are mean values ± standard deviations. Statistical analysis: One-way ANOVA with Tukey’s multiple comparisons in ( e – g ) and Two-tailed unpaired t -test in ( i ) (**** P ≤ 0.0001, NS: not significant). i , j Created with BioRender.com released under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International license.

Article Snippet: Fresh REcN and SW-REcN (REcN released from SGF + SIF-treated WS/REcN) were collected to assess their antimicrobial activity against the gut pathogen Shigella flexneri ( S. flexneri , 12022 GFP, ATCC, USA).

Techniques: Fluorescence, Microscopy, In Vitro, Activity Assay, In Vivo, Imaging, Two Tailed Test